Adverse cognitive effects linked to polychlorinated biphenyls (PCBs) exposure, a type of endocrine-disrupting chemical (EDC), have the potential to be passed down through generations, according to an animal study being presented Thursday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Breast cancer medications, called aromatase inhibitors, may lessen the effect of weight loss drugs, according to a new study being presented Friday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Prenatal exposure to chemicals called phthalates, which are used in hundreds of products, may lead to hormonal changes in females that could affect their future fertility, suggests a study in mice being presented Thursday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Early-time restricted feeding, a type of intermittent fasting, improved fluctuations in blood glucose levels and decreased time above range, according to research being presented Thursday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Children and teenagers who use continuous glucose monitors (CGM) to manage diabetes often fail to use the appropriate alarm settings to alert to dangerously low or harmful high blood sugar levels, according to a study being presented Thursday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill. This variability makes the monitors less useful in tracking glucose levels.
A medication called bempedoic acid reduced the risk of cardiac events as well as statins and may offer an alternative to the popular cholesterol-reducing medications, according to industry-supported research being presented Thursday at ENDO 2023, the Endocrine Society’s annual meeting, in Chicago, Ill.
Fewer than six hours or more than 10 hours of sleep, and poor quality of sleep are associated with a greater risk for diabetes, according to research being presented Thursday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
The number of children diagnosed with type 2 diabetes continued to rise in the year following the beginning of the COVID-19 pandemic, according to research being presented Thursday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Many people with type 1 diabetes struggle to exercise safely while keeping their blood sugar levels within a healthy range, according to a study presented Thursday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Breastfeeding can improve the number of insulin-producing cells in the pancreas and increase insulin sensitivity in mothers, helping to protect them against type 2 diabetes in later years, suggests a mice study presented Thursday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
More pregnant women developed gestational diabetes during the COVID-19 pandemic than in the preceding two years, according to research being presented on Thursday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
People with polycystic ovary syndrome (PCOS) have a 47% increased risk for death at a younger age compared with those without the condition, according to research being presented on Sunday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Women living with polycystic ovary syndrome (PCOS) experience greater body image concerns than individuals without the condition, according to research being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
There may be hope for full recovery among men who wish to stop using anabolic-androgenic steroids for muscle growth, according to data being presented on Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
The Cardiovascular Research Foundation (CRF) has announced the TCT 2023 Program Guide is now available. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. TCT 2023 will take place October 23-26 in San Francisco, California, at the Moscone Center and will celebrate 35 years of leading the field.
The National Comprehensive Cancer Network® (NCCN®) is introducing a new global resource to improve thyroid cancer care in low- and middle-income countries at the upcoming World Congress on Thyroid Cancer, in London.
Cedars-Sinai investigators studying the effects of space on stem cells will present their work at the International Society for Stem Cell Research (ISSCR) Annual Meeting June 14-17 in Boston, and are available for interviews throughout the conference.
20240326113011.png&width=400&height=400){kind=logo}
Journalists who register for the fall meeting of the American Chemical Society (ACS) will have access to about 12,000 presentations on topics including agriculture and food, energy and fuels, health and medicine, sustainability and more.
Researchers presenting preliminary data from a clinical trial aimed at discovering a cure for sickle cell disease reveal positive results among its first patients. Sickle cell disease, a genetic blood disorder, is a painful and debilitating condition for which there are few approved therapies.
Cedars-Sinai endocrinologists will share their latest medical research and clinical care improvements at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, June 15-18.
A new study led by Yale Cancer Center shows improved rates of survival and reduced risk of recurrence in patients with non-small cell lung cancer taking osimertinib (TAGRISSO), a targeted therapy, following surgery. Non-small cell lung cancer (NSCLC), the most common type of lung cancer, tends to recur when diagnosed at advanced stages, which makes treatment challenging.
Reporters and bloggers are invited to join top nutrition experts for a dynamic program at NUTRITION 2023. The annual flagship meeting of the American Society for Nutrition runs July 22-25 at the Sheraton Boston and features research announcements, expert discussions, and more.
MEDSIR announced today the results of the PALMIRA trial. This randomized phase 2 study evaluated the safety and efficacy of palbociclib maintenance in combination with second-line endocrine therapy in patients with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer who had showed a confirmed progressive disease on first-line palbociclib plus endocrine therapy-based treatment after having achieved clinical benefit to this regimen.
While the incidence of colorectal cancer (CRC) has dropped significantly among older adults in recent years — a trend attributed to regular screening colonoscopies and lower smoking rates — the opposite is true for people born between 1981 and 1996, who have double the risk compared with people born in 1950. There’s an urgent need to identify more-effective therapies for those younger people: Approximately 58% of patients age 50 or under have advanced, distant disease at the time of diagnosis, and only 14% of that group will survive five years.
An observational cohort study out of Roswell Park Comprehensive Cancer Center demonstrates that race and ethnicity affect a woman’s 21-gene recurrence score, a tool used to determine risk of recurrence and distant metastasis in patients with early-stage, hormone-receptor-positive breast cancer. Based on the expression of 21 cancer-related genes detected in pre-treatment tumor specimens, recurrence score is used routinely in clinical care to identify patients who might benefit from chemotherapy as part of their treatment plan. Scores range from 0-100, with a score of 26 or higher indicating greater risk of recurrence and poorer overall survival.
Research has shown that the immune system doesn’t function properly in patients with multiple myeloma, a blood cancer that occurs when plasma cells — a type of white blood cell — multiply out of control. But a clinical trial led by Jens Hillengass, MD, PhD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, shows that exercise may have the power to strengthen the immune system in those patients, providing a non-pharmaceutical method of helping control the disease.
Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared to the current standard-of-care chemoimmunotherapy, according to results of the Phase III ZUMA-7 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
A new study led by researchers at the American Cancer Society found medical debt is associated with significantly higher cancer mortality rates at the county level in the United States. On average, an estimated 20% of the population carried medical debt. For every one percent increase in the population with medical debt, there was a 1.12 increase in death rates (per 100,000 person-years) from cancer. The findings were presented today at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2-6.
Three clinical trials led by MD Anderson researchers showed positive results with the targeted therapy erdafitinib for patients with FGFR-altered tumors. The data were presented at the 2023 ASCO Annual Meeting.
Sleep medicine experts from the Mount Sinai Health System are presenting new research at SLEEP 2023, the 37th annual meeting of the Associated Professional Sleep Societies running until June 7 in Indianapolis.
In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types. These data from an interim analysis of the Phase II DESTINY-PanTumor02 study, led by The University of Texas MD Anderson Cancer Center, were presented today at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
New research led by an international team supported by the American Cancer Society shows women with an increasing number of regular mammography screening exams prior to diagnosis of breast cancer considerably improved their probability of survival. The findings were presented at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2-6.
A new study led by researchers at the American Cancer Society (ACS) showed people living with cancer with higher reported loneliness have an increased mortality risk. The findings were presented at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2-6.
Cedars-Sinai clinicians and scientists, including Medawar Prize winner Stanley Jordan, MD, and prominent nephrology and immunology investigator Peter Heeger, MD, will share their latest advances in research at the American Transplant Congress (ATC), June 3-7, 2023, in San Diego.
MEDSIR announced today the positive results of the PHERGain trial. This study is the first to use an adaptive design that tailors treatment in the neoadjuvant/adjuvant setting of patients with HER2-positive early breast cancer. The main objective of this trial was to assess the feasibility of a chemotherapy-free strategy based on a dual HER2 blockade with trastuzumab and pertuzumab through a positron emission tomography (PET)-based, pathologic complete response response(pCR)-adapted strategy.
A tiny population of T-cells could serve as a much-needed biomarker—and a potential therapeutic target—for pediatric acute liver failure, according to new research from Children’s Hospital Los Angeles.
Global celebration of 11 years of discovery and lifesaving innovation in immuno-oncology
In addition to presenting Sylvester Comprehensive Cancer Center research findings, Sylvester experts are available at ASCO to share perspectives on a wide variety of topics and studies ranging from breast cancer to sarcoma, prostate cancer, mesothelioma, melanoma, CNS tumors and more.
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. If you’re covering the American Society for Clinical Oncology’s annual meeting, June 2-6 in Chicago, Illinois, see our list of Fred Hutch research highlights at ASCO and contact [email protected] to set up interviews with experts.
A drug combination that shows little overall survival benefit in white men with advanced prostate cancer has a far greater effect in Black men with the disease, according to interim results from a study led by the Duke Cancer Institute.
Children’s Hospital Los Angeles study assessed which anatomic features affect the clinical course for babies born with complete atrioventricular canal (CAVC) defects.
New research from Cleveland Clinic supports the theory that environmental exposures – such as red meat consumption and sugar intake – may play a role in the rising incidence of young-onset colorectal cancer. Researchers found that people younger than age 50 with colorectal cancer had lower levels of citrate, which is created in the process of converting food into energy, compared to older people diagnosed with colorectal cancer.
In response to the opioid epidemic in the United States, interventions to prevent over-prescribing and misuse of opioids were enacted at institutional, state, and federal levels. To assess how changes in the prescribing landscape affected patients, a research team from the Yale COPPER Center examined the rates of both new and persistent opioid prescribing in patients with cancer as well as in patients without cancer, utilizing data from SEER-Medicare.
Dr. Gilberto Lopes will present information on the Access to Oncology Medicines (ATOM) Coalition, a global initiative established by the Union for International Cancer Control and partners to reduce suffering and deaths from cancer in low- and lower middle-income countries by improving patient access to essential cancer medicine. The coalition includes academic medical, pharmaceutical companies, foundations and professional associations such as the American Society for Clinical Oncology (ASCO) and American Society for Clinical Pathology (ASCP).
Established in 1995, the Glaucoma Foundation's Annual Think Tank has significantly increased the number of people around the world working in the field of glaucoma. All of the speakers at this 2-day will attend in person and the conference will be live-streamed on Zoom.
Cedars-Sinai Cancer physician-scientists with expertise in liver, skin, lung, breast, colorectal, pancreatic, brain, prostate and endometrial cancers will be attending the American Society of Clinical Oncology annual meeting June 2-6 in Chicago and are available for in-person or virtual interviews to discuss the latest news and research.
Researchers will delve into the latest research in diabetes, obesity, reproductive health and other aspects of endocrinology during the Endocrine Society’s ENDO 2023 news conferences June 15-18.
Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers. The results of these studies, along with dozens of others led by Dana-Farber researchers, will be presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
